The use of obesity medications has skyrocketed in Piteå and across Sweden, with sales increasing dramatically in recent years. According to data from E-hälsomyndigheten, obesity medications worth 24 million kronor have been sold in the Piteå region alone. The weight-loss drug Mounjaro has become Sweden's most sold prescription medication, despite not being covered by the national drug benefit scheme, requiring users to pay the full cost themselves.
In Region Norrbotten, sales of obesity medications through Apotek Hjärtat increased by 126 percent during 2025 compared to previous years. Nationally, the pharmacy chain saw an 86 percent increase in obesity medication sales in 2025 compared to 2024. Oliver Ennefors, a pharmacist at Hjärtat in Piteå, confirmed the significant sales growth, describing a "constant stream of customers" seeking the medications.
The medications have positive potential but are no quick fix
While acknowledging the benefits of these medications, medical experts are raising concerns. Overläkare Joakim Bunne, who works at Hortlax health center and serves as a medical advisor for Region Norrbotten's primary care, warns that necessary long-term lifestyle changes may be overlooked. "The medications have positive potential but are no quick fix," Bunne stated. The trend is also affecting obesity surgery rates, with some regions reporting decreases in bariatric procedures as more patients opt for pharmaceutical treatments.